U.S. waives tariffs on certain speciality drugs from 20 countries, including India

This development highlights the complexities of global supply chains in the pharmaceutical industry and the use of trade policy tools like ad valorem tariffs (taxes based on the assessed value of an item) to protect domestic industries. The U.S. action falls under Section 232 of the Trade Expansion Act, a controversial provision allowing the President to impose tariffs on national security grounds. For India, known as the 'pharmacy of the world', the exemption on speciality drugs is a positive signal, but the underlying push for domestic U.S. production of patented drugs and active pharmaceutical ingredients (APIs) could have long-term implications for Indian pharmaceutical exports. The distinction made between patented and generic drugs, with generics being exempt from these specific tariffs, underscores the continued reliance of the U.S. market on cost-effective generic medicines, an area where India dominates.

The tariff waiver is selectively applied to countries that have a current or forthcoming trade and security framework agreement with the U.S. This demonstrates the increasing linkage between trade policy, geoeconomics, and strategic partnerships. India's inclusion in this list of 20 countries, alongside allies like Japan, South Korea, and the European Union, reflects its growing strategic alignment with the U.S. in ensuring resilient global supply chains, a key focus of initiatives like the Indo-Pacific Economic Framework for Prosperity (IPEF). The exemption acts as an economic incentive and reinforces bilateral economic ties, showing how domestic protectionist measures in the U.S. are carefully calibrated to minimize disruptions with key strategic partners.

The targeted nature of the tariff waiver—specifically focusing on drugs for rare diseases (orphan drugs), cell and gene therapies, and antibody-drug conjugates (ADCs)—highlights the critical nature of these advanced therapeutics. These are highly specialized, often very expensive treatments where global manufacturing capacity is concentrated. Imposing tariffs on these specific, life-saving categories could have disrupted critical medical supplies and increased healthcare costs significantly. By exempting these speciality drugs and their components, the policy balances the goal of domestic manufacturing resilience with the immediate need to ensure patient access to essential, high-tech medical treatments that are currently integrated into complex, multi-country supply chains.